|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:physicist
GIP receptor agonist
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2022
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
SURPASS-1
SURPASS-2
SURPASS-3
SURPASS-4
SURPASS-5
|
|
gptkbp:combatants
|
gptkb:GLP-1_receptor
GIP receptor
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
gptkb:medullary_thyroid_carcinoma
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:financial_performance
|
up to 28 days at room temperature
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tirzepatide
|
|
gptkbp:indication
|
weight management
|
|
gptkbp:ingredients
|
C40 H57 N7 O10 S
|
|
gptkbp:interacts_with
|
gptkb:Company
other GLP-1 receptor agonists
oral medications for diabetes
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
A10 B X07
|
|
gptkbp:is_effective_against
|
improves glycemic control
promotes weight loss
reduces Hb A1c levels
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:market
|
gptkb:2022
|
|
gptkbp:marketed_as
|
Mounjaro
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 5 days
|
|
gptkbp:population
|
adults
|
|
gptkbp:research_areas
|
endocrinology
metabolic disorders
obesity treatment
|
|
gptkbp:side_effect
|
nausea
vomiting
decreased appetite
diarrhea
constipation
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:type_of
|
202202-51-1
|
|
gptkbp:utilizes
|
weekly
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
3
|